"Drill-free fillings" company vVardis (VVVV.US) launches a US$214 million US IPO, with pricing expected this week.

date
14:25 09/11/2026
avatar
GMT Eight
Caries treatment company vVardis announces terms for a US$214 million US IPO.
vVardis Holding (VVVV.US), which sells a proprietary drill-free cavity treatment, announced the terms of its IPO on Friday. The Zug, Switzerland-based company plans to offer 9.5 million shares at a price range of $21 to $24 to raise $214 million. At the midpoint of the range, vVardis Holding would have a market value of approximately $1.3 billion. vVardis develops and sells Curodont, a peptide-based treatment for early cavities that can be performed in a dental office in five minutes or less, with no drilling and no injections. Its U.S. product, Curodont Repair Fluoride Plus, is sold as an over-the-counter drug under an FDA monograph and accounts for the vast majority of the company's revenue; a fluoride-free version, Curodont Repair, is sold as a medical device in the U.K. and parts of Europe. In the U.S., the company distributes exclusively through Henry Schein, supported by its own sales team. vVardis Holding was founded in 2020 and had revenue of $50 million for the 12 months ended June 30, 2026. The company plans to list on the New York Stock Exchange under the symbol VVVV. Goldman Sachs Group, Inc., JPMorgan, William Blair, the investment banking division of UBS Group AG, and Deutsche Bank Aktiengesellschaft are serving as joint bookrunners on the deal. Pricing is expected in the week of Monday, November 9, 2026.